Publications by authors named "E Soaly"
Article Synopsis
- Three different strategies exist for starting warfarin: fixed dosing (FWD), clinical dosing (CWD), and genetic-guided dosing (GWD), with GWD shown to be superior in some trials.
- In a study comparing CWD and FWD, researchers found no significant difference in time spent within the therapeutic range or in extreme INR levels between the two methods.
- The conclusion is that CWD did not provide better anticoagulation quality compared to FWD, suggesting that fixed dosing may continue to be a viable option.
Background: Coronavirus disease 2019 (COVID-19) pandemic has resulted in unprecedented pressure on healthcare systems and led to widespread utilization of telemedicine or telehealth services. Combined with teleclinics, using drive-up fingerstick International normalized ratio (INR) testing was recommended to decrease exposure risk of anticoagulation patients.
Objective: To evaluate the impact of transitioning from clinic-based anticoagulation management services to drive-up and phone-based services during COVID-19 pandemic in Qatar.
Anticoagulation clinic drive-up service during COVID-19 pandemic in Qatar.
J Thromb Thrombolysis
February 2021
Coronavirus Disease 2019 (COVID-19) is a pandemic affecting many countries worldwide. Given the increasing incidence especially in elderly and individuals with comorbid conditions, it is advised by health authorities to stay home if possible, maintain social distancing and stay away from those who are sick or could be infected. Patients with comorbidities especially cardiovascular disease are at higher risk of getting infected with COVID-19 and have worse prognosis.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates how genetic variants (VKORC1, CYP2C9, and CYP4F2) affect warfarin dosing in Qatari patients.
- One hundred and fifty warfarin-treated patients were analyzed, revealing that certain genetic variants lead to a lower required warfarin dose.
- The findings highlight that VKORC1 and CYP2C9 variants are key predictors of dose variability, along with factors like hypertension and smoking, accounting for 39.2% of the variability in dosing.